Cohort study
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease
- Retrospective cohort study
- multicentre
- 4 European adults with congenital heart disease (ACHD) centres
- before-after comparison
Authors' conclusion
SGLT2i generally seem safe, well-tolerated, and potentially beneficial in patients with ACHD. SGLT2i was associated with a 3-fold reduction in the 6-month HF hospitalization rate.
Study context
- Population
- Adults with congenital heart disease (ACHD) treated with SGLT2i, April 2016 to July 2023
- Participants
- 174 adults
- Exposure
- 6 months after vs 6 months before starting SGLT2i
- SGLT2in = 174
- Outcome
- Safety, tolerability and short-term heart failure (HF)-related effects (side effects, discontinuation, mortality, hospitalizations)
Main finding
HF hospitalization rate · 6 months before vs 6 months after starting SGLT2i
Relative rate
0.30
95% CI 0.14–0.62
P = 0.001
As reported in the abstract
Observational data: associations, not effects.
Safety
| Outcome | Values |
|---|---|
| Side effects, discontinuation, death · median follow-up 7.7 months | SGLT2i Side effects 18 (10.3%) · Permanent discontinuation 12 (6.9%) · Death (SGLT2i-unrelated causes) 4 (2.3%) |
Original publication
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease. J Am Coll Cardiol. Published 25 March 2024. doi:10.1016/j.jacc.2024.02.017
Summarised from the published abstract; every number is checked against it